Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

Silvia Novello  
*University of Turin*

Giorgio V. Scagliotti  
*University of Turin*

Rafael C. Rosell  
*Catalan Institute of Oncology*

Mark A. Socinski  
*University of North Carolina at Chapel Hill*

Julie R. Brahmer  
*Sidney Kimmel Comprehensive Cancer Center*

*See next page for additional authors*

Follow this and additional works at: [https://digitalcommons.wustl.edu/open_access_pubs](https://digitalcommons.wustl.edu/open_access_pubs)

**Recommended Citation**

Novello, Silvia; Scagliotti, Giorgio V.; Rosell, Rafael C.; Socinski, Mark A.; Brahmer, Julie R.; Atkins, James N.; Palleres, Cinta; Burgess, Russell E.; Tye, Lesley; Selaru, Paulina; Wang, Erjian; Chao, Richard; and Govindan, Ramaswamy, "Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer." British Journal of Cancer. 101,9. 1543-1548. (2009). [https://digitalcommons.wustl.edu/open_access_pubs/4069](https://digitalcommons.wustl.edu/open_access_pubs/4069)

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

S Novello*1, GV Scagliotti2, R Rosell3, MA Socinski4, J Brahmer4, J Atkins5, C Pallares6, R Burgess7, L Tye8, P Selaru9, E Wang9, R Chao9 and R Govindan9

1Department of Clinical and Biological Sciences, Thoracic Oncology Unit, University of Turin, Orbassano, Italy; 2Department of Medical Oncology, Catalan Institute of Oncology, Barcelona, Spain; 3Division of Hematology/Oncology, University of North Carolina, Chapel Hill, NC, USA; 4Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Cockeysville, MD, USA; 5Southeastern Medical Oncology Center, Goldsboro, NC, USA; 6Department of Oncology, Hospital de San Pablo, Barcelona, Spain; 7Department of Internal Medicine, Eastern Carolina Internal Medicine, Pollocksville, NC, USA; 8Pfizer Global Research and Development, La Jolla, CA, USA; 9Department of Medicine, Washington University School of Medicine, St Louis, MO, USA

BACKGROUND: Sunitinib malate (SUTENT) has promising single-agent activity given on Schedule 4/2 (4 weeks on treatment followed by 2 weeks off treatment) in advanced non-small cell lung cancer (NSCLC).

METHODS: We examined the activity of sunitinib on a continuous daily dosing (CDD) schedule in an open-label, multicentre phase II study in patients with previously treated, advanced NSCLC. Patients ≥ 18 years with stage IIIB/IV NSCLC after failure with platinum-based chemotherapy, received sunitinib 37.5 mg per day. The primary end point was objective response rate (ORR). Secondary end points included progression-free survival (PFS), overall survival (OS), 1-year survival rate, and safety.

RESULTS: Of 47 patients receiving sunitinib, one patient achieved a confirmed partial response (ORR 2.1% (95% confidence interval (CI) 0.1, 11.3)) and 11 (23.4%) had stable disease (SD) ≥ 8 weeks. Five patients had SD > 6 months. Median PFS was 11.9 weeks (95% CI 8.6, 14.1) and median OS was 37.1 weeks (95% CI 31.1, 69.7). The 1-year survival probability was 38.4% (95% CI 24.2, 52.5). Treatment was generally well tolerated.

CONCLUSIONS: The safety profile and time-to-event analyses, albeit relatively low response rate of 2%, suggest single-agent sunitinib on a CDD schedule may be a potential therapeutic agent for patients with advanced, refractory NSCLC.

British Journal of Cancer (2009) 101, 1543–1548. doi:10.1038/sj.bjc.6605346 www.bjcancer.com

© 2009 Cancer Research UK

Keywords: non-small cell lung cancer; phase II; sunitinib; tyrosine kinase inhibitor

Vascular endothelial growth factor (VEGF) and the platelet-derived growth factor (PDGF) signalling pathways are critical components in the pathogenesis of non-small cell lung cancer (NSCLC) (Kokourakis et al, 1997; Yuan et al, 2001; Shikada et al, 2005). Clinical data with the anti-VEGF monoclonal antibody, bevacizumab, plus first-line chemotherapy improved efficacy in patients with advanced NSCLC (Sandler et al, 2006; Manegold et al, 2007, 2008), indicating that targeting angiogenesis through VEGF is a viable strategy. Furthermore, preclinical data suggest that concomitant inhibition of VEGF and PDGF signalling may improve antitumour activity compared with VEGF inhibition alone (Shikada et al, 2005; Potapova et al, 2006; Hasumi et al, 2007).

Sunitinib is an oral multitargeted tyrosine kinase inhibitor of VEGF receptors (VEGFRs 1–3) and PDGF receptors (PDGFRs α and β), as well as other receptor types, and is approved multinationally for the treatment of advanced renal cell carcinoma (RCC) and imatinib-resistant or -intolerant gastrointestinal stromal tumours (GISTs) (Abrams et al, 2003; Mendel et al, 2003; Murray et al, 2003; O’Farrell et al, 2003; Kim et al, 2006). In preclinical studies, sunitinib decreased tumour growth in NSCLC NCI-H460 xenograft models, with tumour growth inhibition ranging from 56 to 85% (Christensen, 2008). Further, in a phase II trial of single-agent sunitinib, we reported an objective response rate (ORR) of 11.1% (95% confidence interval (CI) 4.6, 21.6) in heavily pretreated patients with advanced NSCLC. Median progression-free survival (PFS) was 12.0 weeks (95% CI 10.0, 16.1) and overall survival (OS) was 23.4 weeks (95% CI 17.0, 28.3). Sunitinib was administered intermittently at 50 mg per day on Schedule 4/2 (4 weeks on treatment followed by 2 weeks off treatment) and was well tolerated (Socinski et al, 2008).

Following reports from a phase II sunitinib study in metastatic breast cancer (Burstein et al, 2008) suggesting that some patients had increases in the size of the superficial lesions during the 2-week off-treatment period, it was hypothesised that better tumour control could be achieved with sunitinib given once daily on a continuous daily dose (CDD) schedule. Although CDD and Schedule 4/2 have not been compared head-to-head in one trial, subsequent trials of sunitinib using a CDD schedule in patients with RCC and with GIST indicate that this regimen is well tolerated, associated with broadly similar clinical activity to Schedule 4/2, and provides flexibility in dosing schedule (GIST: median PFS 34 weeks and 24 weeks for sunitinib on CDD.
and Schedule 4/2, respectively; RCC: median PFS 8.2 months for both sunitinib on CDD and Schedule 4/2 (Motzer et al, 2006, 2007; George et al, 2007, 2009; Escudier et al, 2009). Here we report the efficacy and safety of sunitinib 37.5 mg per day given as a CDD schedule in an additional cohort of patients, after failure of a platinum-based regimen.

MATERIALS AND METHODS

Study population

Patients 18 years or older, with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and histologically proven stage IIIB (with pleural or pericardial effusion) or stage IV NSCLC were recruited. All patients had received previous treatment with no more than two chemotherapy regimens (at least one platinum based), had unidimensional measurable disease at baseline, and evidence of disease progression within 6 months of their most recent prior systemic anticancer treatment.

Patients were excluded if they had a history of, or known, brain metastases; gross haemoptysis (>5 ml per episode or >10 ml per day) <4 weeks before start of study; hypertension (>160/90 mmHg) that could not be controlled with standard antihypertensive agents; cardiac disease, cerebrovascular accident or pulmonary embolism; left ventricular ejection fraction (LVEF) that was below the lower limit of normal; cardiac dysrhythmias of National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 2; atrial fibrillation of any grade; prolongation of the QTc interval (>450 ms for males or >470 ms for females); previous treatment with an antiangiogenic agent, including thalidomide or inhibitors of PDGFR (previous treatment with gefitinib or erlotinib was permitted); or grade 3 haemorrhage <4 weeks before start of study.

Study design and treatment

This open-label, multicentre, phase II trial conducted in the United States and Europe analysed sunitinib administered on Schedule 4/2 and on a CDD schedule. Investigations of the two treatment schedules were performed in separate cohorts of patients. Patients in the CDD cohort were recruited from the same study sites at which the Schedule 4/2 was analysed, after completion of enrolment in the Schedule 4/2 cohort and observation of the requisite number of responses on Schedule 4/2. Results from the Schedule 4/2 cohort have been published (Socinski et al, 2008).

Patients received once-daily sunitinib in 4-week cycles at a starting dose of 37.5 mg per day. Dose escalation was permitted to 50 mg per day after two cycles (first 8 weeks of treatment) if patients experienced grade ≤1 non-haematologic toxicity or grade ≤2 haematologic toxicity attributed to sunitinib. Patients experiencing sunitinib-related toxicity requiring treatment interruption or dose reduction (NCI-CTCAE grade 3/4) could receive a reduced dose (25 mg per day). Treatment was administered for up to 13 cycles or until disease progression or withdrawal of consent. Patients deriving clinical benefit after completing 13 cycles could continue to receive sunitinib through participation in a separate protocol.

The study was approved by the institutional review board of each participating centre and carried out in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines, and applicable local laws and regulatory requirements.

Study assessments

The primary end point was objective response as measured by the confirmed ORR, defined as the proportion of patients with a confirmed complete response (CR) or confirmed partial response (PR). Response was determined using radiologic tumour assessments and the Response Evaluation Criteria for Solid Tumours (RECIST) (Therasse et al, 2000). Secondary end points included PFS, OS, and 1-year survival rate. Tumour imaging, including CT or MRI scans of the chest, abdomen, and pelvis and other applicable sites of disease, was performed on day 1 of even-numbered cycles, whenever disease progression was suspected, to confirm a CR or PR (at least 4 weeks after initial documentation of response), and at the end of study treatment or withdrawal from the study (if an assessment was not performed within the previous 6 weeks). Tumour scans were not reviewed centrally.

Safety assessments included physical examinations, laboratory tests, vital signs, and 12-lead electrocardiogram (ECG). Adverse events (AEs) and serious AEs (SAEs) were graded according to the NCI-CTCAE version 3.0. Pharmacokinetic (PK) parameters analysed included plasma trough concentrations at steady-state for sunitinib, its primary active metabolite, SU12662, and sunitinib plus SU12662 (total drug), determined on day 1 of cycles 1–13.

Statistical analysis

Depending on the number of objective responses observed on Schedule 4/2, sample size for the CDD cohort was determined using either a two-stage design (if ≤5 confirmed objective responses were observed) or a single-stage design (if ≥6 confirmed objective responses were observed). As there were seven confirmed objective responses on Schedule 4/2, the sample size on the CDD schedule was based on a single-stage design with an α level of 10 and 80% power. This design required 44 patients to test the null hypothesis that the true response rate was ≤5% vs the alternative hypothesis that the true response rate was ≥15%. At the end of the study, if ≥5 objective tumour responses were observed on the CDD schedule, then the null hypothesis was to be rejected. The study population for efficacy and safety analyses included all patients enrolled into the study who received at least one dose of sunitinib.

RESULTS

Patient characteristics

In total, 47 patients were enrolled into the CDD cohort. The first patient entered the study in November 2005, and the last patient entered the study and received sunitinib in May 2006; baseline characteristics are summarised in Table 1. The median age of patients was 60 years, and most patients were male (n = 27, 57.4%), smokers (n = 40, 85.1%), and had an ECOG performance status of 0 or 1 (n = 46, 97.8%). Most patients (57.5%) had adenocarcinoma. Commonly reported sites of disease included the lung, lymph nodes, bone, and liver. Of the six patients with stage IIIB disease, four had pleural effusion. In total, 28 patients (59.6%) had received at least two previous systemic regimens.

Exposure to study drug

Of the 47 patients included in the analyses, nine patients discontinued treatment during cycle 1 because of AEs (n = 4) or disease progression (n = 5). Overall, patients received a median of three treatment cycles (range: 1–12) and was administered sunitinib for a median of 68 days (range: 11–331).

Dosing modifications were required in 15 patients (31.9%), including 14 patients (29.8%) with dose reductions to 25 mg and one patient with dose escalation to 50 mg (as permitted per protocol). Dose interruption occurred in 17 patients (36.2%); the most frequently reported reason for dose interruptions and delays was grade 3/4 haemorrhage (n = 10); at least 4 weeks before start of study. Tumour scans were not reviewed centrally.
was AEs (n = 14 patients, 29.8%), including hypertension (n = 5, 10.6%), nausea, fatigue, and skin reaction (each: n = 3, 6.4%). Treatment discontinuation was primarily due to disease progression (n = 34, 72.3%). In addition, 12 patients (25.5%) discontinued because of AEs; for six of these patients, AEs were considered to be related to study treatment and included lymphopenia, peripheral neuropathy, respiratory failure, vomiting (all n = 1, grade 3), asthenia, skin toxicity (both n = 1, grade 2), and fatigue (n = 2, grade 2). One patient discontinued in order to receive sunitinib on a continuation protocol (no other patients continued to receive sunitinib after study end on a continuation protocol). Seven patients (15%) received at least 9 cycles of sunitinib therapy, and the longest duration of treatment in this study was 12 cycles (approximately 1 year).

Efficacy

One patient achieved a confirmed PR (ORR: 2.1%, 95% CI 0.1, 11.3; Figure 1) observed at cycle 8 and confirmed at cycle 10; the duration of response was 24.4 weeks. This patient (64-year-old white male) had stage IV adenocarcinoma with lung metastases and received 12 cycles of sunitinib (37.5 mg per day reduced to 25 mg per day in cycles 2 onwards because of grade 3 skin reaction and hypertension). Eleven patients (23.4%) showed stable disease (SD) (>8 weeks), which lasted for >3 months in 10 patients (one of whom had received previous therapy with gefitinib). Of these 10 patients, five had SD for >6 months. Of the five patients with SD >6 months, all had stage IV disease and tumour types included adenocarcinoma (one patient with bone metastases and the second with lung metastases), squamous cell carcinoma (liver metastases), large cell carcinoma (liver metastases), and large cell neuroendocrine carcinoma (with lung metastases). These patients received 7–12 cycles of sunitinib (two patients received dose reductions from 37.5 to 25 mg per day in cycles 2 or 3 for the duration of study treatment).

The median PFS was 2.7 months (11.9 weeks, 95% CI 8.6, 14.1; Figure 2A) and median OS was 8.6 months (37.1 weeks, 95% CI 31.1, 69.7; Figure 2B). The 1-year survival was 38.4% (95% CI 24.2, 52.5).

Safety

The most commonly reported AEs (all causality) were generally mild-to-moderate (grade 1/2) (severity) (Table 2). Grade 3/4 AEs included fatigue/asthenia (17.0%), hypertension (8.5%), and dyspnoea (6.4%; Table 2). Four patients (8.7%) experienced grade 3 neutropenia, while no patients experienced febrile neutropenia or grade ≥3 anaemia or thrombocytopenia. Two subjects experienced grade 3 bleeding events (haemoptysis and gastric haemorrhage, respectively); neither was assessed to be related to study drug. The haemoptysis was reported in a 78-year-old white male who had stage IV squamous cell carcinoma with lung metastases with a history of gastroesophageal reflux disease who received sunitinib 37.5 mg per day for 49 days. The patient recovered without sequelae. No subjects reported grade 4 or 5 bleeding events.

The most common AEs attributed to sunitinib treatment were diarrhoea (n = 13, 27.7%), fatigue (n = 13, 27.7%), hypertension (n = 11, 23.4%), and erythema (n = 10, 21.3%). Seven patients died on study (within 28 days of receiving the last dose of study medication), including four patients who died because of disease progression and one patient because of clinical deterioration (49-year-old male, 22 days after the first dose). One patient died because of pulmonary embolism (72-year-old male with stage IIIIB squamous cell carcinoma and pleural effusion, and comorbidities of controlled chronic obstructive pulmonary disease and hypercholesterolaemia). He was admitted to hospital after developing...
Clinical Studies

of drug accumulation over treatment cycles.

and SU12662 combined was approximately 50 ng ml$^{-1}$ and was

median steady-state plasma trough concentration of sunitinib

British Journal of Cancer (2009)

treatment cycles were 31–56 and 11–18 ng ml$^{-1}$, respectively. The

plasma concentration ranges of sunitinib and SU12662 across

SU12662 were observed throughout the study. The median trough

Pharmacokinetics

Figure 2 (A) Progression-free survival (PFS) and (B) overall survival (OS) Kaplan–Meier plots. Probability of survival at 1 year was 38.4% (95% CI 24.2, 52.5).

dyspnea with accompanying bronchospasm approximately 2

months after starting sunitinib 37.5 mg per day, and approxima-
tely 1 week after dose reduction to 25 mg per day because of nausea

and vomiting. Chest radiograph revealed increased left haemo-
thorax opacity with pleural effusion, and lung collapse. Pulmonary

embolism (unrelated to study treatment) as well as disease

progression was noted on chest CT and the patient died 1 day

months after starting sunitinib 37.5 mg per day, and approxima-
tively 34%, respectively).

This phase II trial was not designed to compare the antitumour

activity observed on Schedule 4/2 and the CDD schedule. A higher

Anterior isosulfan blue leakage was noted on the lateral view and

DISCUSSION

Aberrant signalling in multiple pathways has a critical role in the

pathogenesis of NSCLC. Inhibition of a specific, single pathway

may stimulate activation of another to resume growth of the

tumour and/or its associated blood vessels. Co-inhibition of VEGF

and PDGF pathways potentially offers greater antiangiogenic effect

than inhibition of either pathway alone (Potapova et al, 2006).

However, it is possible that broader antitumour activity may also

translate into a less favourable safety profile due to off-target

toxicity.

Favourable antitumour activity and tolerability data with single-

agent sunitinib, an inhibitor of VEGFRs and PDGFRs, in the

intermittent (Schedule 4/2) dose cohort of this trial were reported

earlier (Socinski et al, 2008). The CDD schedule was analysed to

provide flexibility in the dosing schedule and was based on the

hypothesis that better tumour control could be achieved with

sunitinib given on a CDD schedule.

In this CDD cohort, analysing sunitinib 37.5 mg per day in

patients with advanced platinum-refractory NSCLC, SD (≥ 8

weeks) and PR were observed in 11 patients and 1 patient,

respectively. The frequency of liver (n = 4, 33%) and bone (n = 3,

25%) metastases at baseline observed in the 12 patients with SD or

PR was similar to that reported in the overall CDD cohort (28 and

34%, respectively).

This phase II trial was not designed to compare the antitumour

activity observed on Schedule 4/2 and the CDD schedule. A higher

ORR was observed on Schedule 4/2 (11.1%) vs CDD (2.1%), and a

higher median OS was observed on the CDD schedule (37.1 vs 23.4

weeks, respectively). Median PFS was similar on both treatment

schedules (12.0 and 11.9 weeks). Although the ORR (2.1%)

observed in the CDD cohort did not meet the pre-specified

criterion required to reject the null hypothesis, the observed OS

and PFS suggest that CDD of sunitinib provides clinical benefit to

patients with advanced NSCLC.

Pharmacokinetics

Steady-state trough plasma concentrations of sunitinib and

SU12662 were observed throughout the study. The median trough

plasma concentration ranges of sunitinib and SU12662 across

treatment cycles were 31–56 and 11–18 ng ml$^{-1}$, respectively. The

median steady-state plasma trough concentration of sunitinib

and SU12662 combined was approximately 50 ng ml$^{-1}$ and was

consistent across cycles (44–73 ng ml$^{-1}$), providing no evidence of

drug accumulation over treatment cycles.

Table 2 Incidence (%) of the most common (≥ 10%) treatment-

emergent (all-causality) non-haematologic AEs

| Adverse event * | Grade 3 n (%) | Grade 4 n (%) | Total b n (%) |
|-----------------|---------------|---------------|---------------|
| Fatigue/asthena | 7 (14.9)      | 1 (2.1)       | 28 (59.6)     |
| Pain/myalgia    | 1 (2.1)       | 0             | 23 (48.9)     |
| Nausea/vomiting | 1 (2.1)       | 0             | 19 (40.4)     |
| Diarrhoea       | 0             | 0             | 16 (34.0)     |
| Stomatitis/mucosal inflammation | 1 (2.1) | 0 | 15 (31.9) |
| Hypertension    | 4 (8.5)       | 0             | 13 (27.7)     |
| Cough           | 0             | 0             | 12 (25.5)     |
| Dyspnoea        | 3 (6.4)       | 0             | 12 (25.5)     |
| Dysgeusia       | 0             | 0             | 10 (21.3)     |
| Erythema        | 1 (2.1)       | 0             | 10 (21.3)     |
| Dizziness       | 0             | 0             | 9 (19.1)      |
| Dyspepsia       | 0             | 0             | 9 (19.1)      |
| Oedema peripheral | 0             | 0             | 9 (19.1)      |
| Anorexia/weight decreased | 0 | 0 | 8 (17.0) |
| Haemoptysis     | 1 (2.1)       | 0             | 8 (17.0)      |
| Headache        | 0             | 0             | 8 (17.0)      |
| Constipation    | 0             | 0             | 7 (14.9)      |
| Ageusia         | 0             | 0             | 6 (12.8)      |
| Skin reaction   | 1 (2.1)       | 0             | 6 (12.8)      |
| Arthralgia      | 0             | 0             | 5 (10.6)      |

Abbreviation: AEs = adverse events. *Adverse events graded according to NCI CTCAE v3.0, worst per patient. bGrade 1 – 4 AEs (n = 7) and grade 5 AEs were reported.
It is noteworthy that the median PFS (11.9 weeks (2.7 months)) and OS (37.1 weeks (8.6 months)) in the CDD cohort of this trial are comparable to the currently available treatment options for this setting as shown in phase III studies, including docetaxel (time to progression (TTP) 10.6 weeks, OS 7.0 months), erlotinib (PFS 2.2 months, OS 6.7 months), and pemetrexed vs docetaxel (PFS 2.9 months in both arms, OS 8.3 and 7.9 months, respectively), (Shepherd et al, 2000, 2005; Hanna et al, 2004). Interestingly, PFS observed with sorafenib monotherapy in this treatment setting was 2.8 months (Gatzemeier et al, 2006). However, caution is required when interpreting antitumour activity across clinical trials of different agents with differences in clinical trial design and baseline characteristics of patients.

The sunitinib AE profile observed in the CDD cohort was tolerable and manageable. The most frequent treatment-related AEs were consistent with common conditions associated with advanced NSCLC and known toxicities of sunitinib. Most were mild-to-moderate in severity and were managed adequately with supportive measures, with or without dose modification. Although formal comparisons cannot be made between the safety profiles of sunitinib on Schedules 4/2 vs CDD, among the commonly reported toxicities, constitutional (e.g., fatigue/asthenia: 69.8% vs 59.6%) and gastrointestinal (e.g., nausea/vomiting: 52.4% vs 40.4%) AEs appeared to be less frequent on the CDD schedule, notwithstanding the longer median treatment duration on the CDD schedule compared to Sunitinib on the 4/2 schedule in combination with erlotinib 150 mg per day is currently ongoing.

ACKNOWLEDGEMENTS

Editorial assistance was provided by ACUMED (Tytherington, UK) and was funded by Pfizer Inc. This study was sponsored by Pfizer Inc.

Conflict of interest

R Chao, P Selaru, L Tye, and E Wang are employees of Pfizer Inc. and hold stock in Pfizer Inc., the makers of SUTENT.

REFERENCES

Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2: 771–778

Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Christensen JG (2008) Antitumor efficacy of sunitinib malate in concurrent combination therapy targeting PDGF and VEGF signaling. Int J Cancer 121: 2606–2614

Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, Park SH, Hwang JH, Rha SY, Kweon GR, Lee SJ, Jo KW, Shong M (2006) An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91: 4070–4076

Koukourakis MI, Giattromanolaki A, O’Byrne KJ, Comley M, Whitehouse RM, Talbot DC, Gatter KC, Harris AL (1997) Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. Br J Cancer 75: 477–481

Manegold C, Von Pawel J, Zatloukal P, Ramlau R, Gorbunova V, Hirsh V, Leighton N, Mezger J, Archer V, Reck M (2008) BOI7704 (AVAIL): a phase III randomised study of first-line bevacizumab combined with cisplatin/gemcitabine (CG) in patients (pts) with advanced or recurrent non-squamous, non-small-cell lung cancer (NSCLC). Ann Oncol 19: LB11

Manegold C, Von Pawel J, Zatloukal P, Ramlau R, Gorbunova V, Hirsh V, Leighton N, Mezger J, Moore N, Reck M (2007) Efficacy and safety results from BOI17704, a randomised, placebo-controlled phase III study of bevacizumab in combination with cisplatin and gemcitabine in patients with advanced or recurrent non-squamous non-small-cell lung cancer (NSCLC). Eur J Cancer Suppl 5: S55 (abstract)

Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Wilding G (2007) Sunitinib efficacy against advanced renal cell carcinoma. J Urol 178: 1883–1887

Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295: 2516–2524

Murray LJ, Abrams TJ, Long KR, Ngiaj T, Olson LM, Hong W, Keast PK, Brassard JA, O’Farrell AM, Cherrington JM, Pryer NK (2003) SU11248 inhibits tumor growth and CSF-IR-dependent osteolysis in an
experimental breast cancer bone metastasis model. Clin Exp Metastasis 20: 757 – 766
O’Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101: 3597 – 3605
Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, Cherrington JM, Mendel DB (2006) Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther 5: 1280 – 1289
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilienbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542 – 2550
Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095 – 2103
Shikada Y, Yonemitsu Y, Koga T, Onimaru M, Nakano T, Okano S, Sata S, Nakagawa K, Yoshino I, Maehara Y, Sueishi K (2005) Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas. Cancer Res 65: 7241 – 7248
Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, Tye L, Selaru P, Chao RC, Scagliotti GV (2008) Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26: 650 – 656
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205 – 216
Yuan A, Yu CJ, Kuo SH, Chen WJ, Lin FY, Luh KT, Yang PC, Lee YC (2001) Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 19: 432 – 441

Findlay B, Tu D, Johnston D, Besjak A, Clark G, Santabarbara P, Seymour L (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123 – 132